Want to see JP:4151 full AI Analyst Report?
4151 Stock Chart & Stats
¥2663.50
-¥5.00(-0.19%)
At close: 4:00 PM EDT
¥2663.50
-¥5.00(-0.19%)
Day’s Range― - ―
52-Week Range¥2,109.00 - ¥2,912.00
Previous CloseN/A
Volume875.90K
Average Volume (3M)1.49M
Market Cap
¥1.17T
Enterprise Value¥1.11M
Total Cash (Recent Filing)¥265.08B
Total Debt (Recent Filing)¥22.20B
Price to Earnings (P/E)14.3
Beta0.52
Next Earnings
Oct 29, 2026EPS Estimate
38.01Next Dividend Ex-DateN/A
Dividend Yield3.02%
Share Statistics
EPS (TTM)155.38
Shares Outstanding525,634,500
10 Day Avg. Volume2,313,410
30 Day Avg. Volume1,488,563
Financial Highlights & Ratios
PEG Ratio1.49
Price to Book (P/B)1.48
Price to Sales (P/S)2.66
P/FCF Ratio22.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,600.00Price Target Upside-2.38% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)153.13
Revenue Forecast (FY)¥529.29B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives Kyowa Kirin substantial financial resilience and flexibility. The company can continue funding research, pipeline development, and commercialization without depending heavily on borrowing, helping it withstand business volatility while preserving strategic options.
Strong ProfitabilityHigh gross and operating margins indicate meaningful earnings power from Kyowa Kirin’s prescription-drug portfolio and biotechnology capabilities. Sustained profitability can support ongoing R&D, commercialization investment, and portfolio development while providing a buffer against cost pressure.
Healthy Cash GenerationStrong absolute operating and free cash flow demonstrate that the business is converting commercial activity into substantial internal funding. This supports investment in the pipeline, debt-light growth, shareholder distributions, and resilience through the next several quarters.
Bears Say
Moderating Revenue GrowthSlowing revenue expansion suggests that the current portfolio is not delivering the same acceleration seen during stronger periods. Persistently modest growth could limit operating leverage, reduce reinvestment capacity, and increase reliance on successful pipeline products or lifecycle initiatives.
Net Margin CompressionThe decline in net margin indicates that profitability has not been fully sustained despite strong gross and operating margins. If the compression reflects mix, pricing, or cost pressure, it could reduce earnings conversion and constrain the company’s ability to compound shareholder returns.
Uneven Free Cash Flow TrendAlthough current cash generation is substantial, declining and uneven free cash flow growth reduces visibility into future internal funding. Continued volatility could make investment pacing, distributions, and pipeline spending less predictable even with the company’s strong current liquidity position.
Kyowa Kirin Co News
4151 FAQ
What was Kyowa Kirin Co Ltd’s price range in the past 12 months?
Kyowa Kirin Co Ltd lowest stock price was ¥2109.00 and its highest was ¥2912.00 in the past 12 months.
What is Kyowa Kirin Co Ltd’s market cap?
Kyowa Kirin Co Ltd’s market cap is ¥1.17T.
When is Kyowa Kirin Co Ltd’s upcoming earnings report date?
Kyowa Kirin Co Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 42 days.
How were Kyowa Kirin Co Ltd’s earnings last quarter?
Kyowa Kirin Co Ltd released its earnings results on Aug 03, 2026. The company reported ¥35.49 earnings per share for the quarter, beating the consensus estimate of ¥34.036 by ¥1.454.
Is Kyowa Kirin Co Ltd overvalued?
According to Wall Street analysts Kyowa Kirin Co Ltd’s price is currently Overvalued.
Does Kyowa Kirin Co Ltd pay dividends?
Kyowa Kirin Co Ltd pays a Semiannually dividend of ¥35 which represents an annual dividend yield of 3.02%. See more information on Kyowa Kirin Co Ltd dividends here
What is Kyowa Kirin Co Ltd’s EPS estimate?
Kyowa Kirin Co Ltd’s EPS estimate is 38.01.
How many shares outstanding does Kyowa Kirin Co Ltd have?
Kyowa Kirin Co Ltd has 525,634,500 shares outstanding.
What happened to Kyowa Kirin Co Ltd’s price movement after its last earnings report?
Kyowa Kirin Co Ltd reported an EPS of ¥35.49 in its last earnings report, beating expectations of ¥34.036. Following the earnings report the stock price went down -1.527%.
Which hedge fund is a major shareholder of Kyowa Kirin Co Ltd?
Currently, no hedge funds are holding shares in JP:4151
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyowa Kirin Co Ltd
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
4151 Company Deck
4151 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in North American and EMEA markets, particularly in strategic products like Crysvita and Poteligeo. However, this was offset by declines in overall revenue and interim profit due to restructuring costs and challenges in the Japanese market. While there were strong performances in certain segments and promising R&D developments, the financial declines and restructuring challenges resulted in a mixed sentiment.View all JP:4151 earnings summaries4151 Stock 12 Month Forecast
Average Price Target
¥2,600.00
▼(-2.38% Downside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Daiichi Sankyo Company
―
Eisai Co
―
ONO Pharmaceutical Co
―